The gene defective in Huntington's disease (HD), IT15, encodes a proteins, huntingtin, with unknown function. There is no apparent difference in IT15 RNA expression in control and HD brain, suggesting that the mutation acts at the protein level to cause HD. How the mutation, a polyglutamine expansion at the N-terminal of the protein, affects the properties of hungingtin expression, subcellular localization, and protein interactions within the cell is unknown. Curiously, the expression of IT15 occurs in all tissues, but the disease process affects striatal spiny neurons preferentially. These neurons possess unusual properties which make them vulnerable to the mutation. At present, almost nothing is known about huntingtin in relation to neuropathological changes in HD, the timetable in which the protein is expressed in developing striatal cells, the subcellular compartments in which the wild-type and mutant forms are processed and localized, and the functional alterations which occur in spiny cells expressing the mutant transcript. Information on these biological properties of huntington is vital to understand the pathogenesis of HD and to develop a therapy for treating the disease. Our overall hypothesis is that in the neostriatum the IT15 mutation modifiers the cellular processing and localization of huntingtin preferentially in spiny cells, thus leading to abnormal protein interactions that are functionally harmful to these neurons. Immunohistochemical and in vitro transfection experiments are planned to examine the localization and functional properties of huntingtin. With well-characterized antisera, huntingtin localization will be examined in human control and HD presymptomatic, homozygote, and grade 1-4 HD brains (Aim 1), and in the developing and adult rodent striatum (Aim 2). Transfection of epitope-tagged transcripts into hybrid striatal cells will be used to determine the effects of expression of the mutant form of huntingtin on the transport and processing of the protein (Aim 3a), and on the survival, neurite outgrowth, and response to excitatory amino acids (Aim 3b). These studies should help to define those characteristics of huntingtin neurobiology and its mutation that underlie the marked loss of striatal neurons in HD.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
5P50NS016367-19
Application #
6273652
Study Section
Project Start
1998-07-01
Project End
1999-06-30
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
19
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Lee, Jong-Min; Chao, Michael J; Harold, Denise et al. (2017) A modifier of Huntington's disease onset at the MLH1 locus. Hum Mol Genet 26:3859-3867
HD iPSC Consortium (2017) Developmental alterations in Huntington's disease neural cells and pharmacological rescue in cells and mice. Nat Neurosci 20:648-660
Chao, Michael J; Gillis, Tammy; Atwal, Ranjit S et al. (2017) Haplotype-based stratification of Huntington's disease. Eur J Hum Genet 25:1202-1209
Shin, Aram; Shin, Baehyun; Shin, Jun Wan et al. (2017) Novel allele-specific quantification methods reveal no effects of adult onset CAG repeats on HTT mRNA and protein levels. Hum Mol Genet 26:1258-1267
Keum, Jae Whan; Shin, Aram; Gillis, Tammy et al. (2016) The HTT CAG-Expansion Mutation Determines Age at Death but Not Disease Duration in Huntington Disease. Am J Hum Genet 98:287-98
Correia, Kevin; Harold, Denise; Kim, Kyung-Hee et al. (2015) The Genetic Modifiers of Motor OnsetAge (GeM MOA) Website: Genome-wide Association Analysis for Genetic Modifiers of Huntington's Disease. J Huntingtons Dis 4:279-84
Lee, Jong-Min; Kim, Kyung-Hee; Shin, Aram et al. (2015) Sequence-Level Analysis of the Major European Huntington Disease Haplotype. Am J Hum Genet 97:435-44
Ramos, Eliana Marisa; Gillis, Tammy; Mysore, Jayalakshmi S et al. (2015) Haplotype analysis of the 4p16.3 region in Portuguese families with Huntington's disease. Am J Med Genet B Neuropsychiatr Genet 168B:135-43
Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium (2015) Identification of Genetic Factors that Modify Clinical Onset of Huntington's Disease. Cell 162:516-26
Biagioli, Marta; Ferrari, Francesco; Mendenhall, Eric M et al. (2015) Htt CAG repeat expansion confers pleiotropic gains of mutant huntingtin function in chromatin regulation. Hum Mol Genet 24:2442-57

Showing the most recent 10 out of 42 publications